MALDI

MATTERWORKS ANNOUNCES UPDATES TO LEADERSHIP TEAM

Retrieved on: 
Thursday, May 2, 2024
MALDI, Cancer Institute, AI, HCA, Systems biology, HCA Healthcare, Proteomics, Biomedical Research, Creativity, Mass spectrometry, Applied Biosystems, Medical device

SOMERVILLE, Mass., May 2, 2024 /PRNewswire/ -- Matterworks, Inc., whose foundational AI platform and predictive biology applications accelerate life sciences discovery and development, today announces additions to its leadership team.

Key Points: 
  • SOMERVILLE, Mass., May 2, 2024 /PRNewswire/ -- Matterworks, Inc., whose foundational AI platform and predictive biology applications accelerate life sciences discovery and development, today announces additions to its leadership team.
  • She joined Matterworks from Novartis Institutes of Biomedical Research in 2021 to lead R&D from initial product conceptualization through development and early customer testing.
  • "I could not be more thrilled to have Jenn Campbell and Niall O'Connor as part of the Matterworks organization," said Dr. Jack Geremia, Matterworks CEO.
  • Their talents will advance Matterworks into our next phase of technology leadership and commercial deployment."

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech

Retrieved on: 
Thursday, May 2, 2024
Other Health, Research, Technology, Infectious Diseases, Hospitals, Artificial Intelligence, Semiconductor, Genetics, Science, Biotechnology, Other Science, Health, MALDI, Corporation, MDX, FY, History, Viral, Microbiology, Acquisition, EPS, Infection, IVD, Pharmaceutical industry

Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870 million in cash, excluding the carved out ELITech clinical chemistry business.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870 million in cash, excluding the carved out ELITech clinical chemistry business.
  • “We are very pleased to welcome ELITech to Bruker,” said Frank H. Laukien, Bruker’s President and CEO.
  • “The ELITech molecular diagnostics sample-to-answer platforms for viral infection and other esoteric MDx assays complement our MALDI Biotyper® platform for bacterial and fungal identification.
  • The ELITech team is very much looking forward to becoming part of the Bruker family.”
    Going forward, ELITech will become the Bruker Molecular Diagnostics business within the Bruker Microbiology & Infection Diagnostics division of the Bruker CALID Group.

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Retrieved on: 
Friday, April 26, 2024
Biotechnology, Health, Genetics, Science, Research, MALDI, RUO, Yeast, Infection, Gastroenteritis, Piperacillin/tazobactam, HAI, Hospital, Antimalarial medication, Certification, Mycobacterium tuberculosis, Fungal infection, Bacteria, ESCMID, Daptomycin, Patient, Microbiology, Acquisition, Multimedia, Gram-negative bacteria, Diagnosis, Colistin, IVDR, TB, IVD, Sepsis, MBT, Sirius, Vaccine

At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays.

Key Points: 
  • At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays.
  • Simplifying microbiology and infectious disease diagnostics and workflows in the clinical laboratory is a key goal for Bruker in support of earlier and improved patient treatment decisions.
  • Bruker offers additional clinical workflows for rapid functional antibiotic resistance testing, like the MBT STAR®-Carba IVD assay for the detection of carbapenemase activity.
  • Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division, commented: “Bruker is committed to innovation in routine microbiology and infectious disease testing.

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Other Science, Research, Science, Biotechnology, Acquisition, Hospital, Infection, Cystic fibrosis, Microbiology, MALDI, Mycobacterium, MDX, Fungal infection, PAI Partners, PAI, COVID, BRKR, Tuberculosis, Hand, Corporation, PCR, HIV, IVD, Partnership

This put option has now been exercised, and the parties have entered into a binding share purchase agreement.

Key Points: 
  • This put option has now been exercised, and the parties have entered into a binding share purchase agreement.
  • ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products.
  • Establishing this unique business within Bruker - a well-respected global life-science tools and specialty diagnostics company - provides an exciting opportunity to further grow our molecular diagnostics, microbiology and biomedical systems portfolios.
  • Upon closing, ELITech is expected to be a stand-alone business within Bruker’s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

Journal of Pharmaceutical Analysis Articles Provide Novel Insights into Previously Unknown Disease Mechanisms

Retrieved on: 
Tuesday, February 27, 2024
Nerve, Central nervous system, Metabolism, PXR, Alzheimer's disease, Testosterone, PCN, Research, MSI, Diabetic cardiomyopathy, Inflammation, Pathology, Deficit spending, Pregnane X receptor, MALDI, Neurotoxicity, Dysbiosis, JPA, Hippocampus, CYP, Heart failure, DCM, Domestic airport, Phenytoin, Mass spectrometry, PHT, Triglyceride, TMAO, Transplant, Glucocorticoid, Lipid metabolism, Patient, Journal, Glucose, Heart, Mouse, Glycated hemoglobin, Brain

XI'AN, China, Feb. 27, 2024 /PRNewswire/ -- DCM is the leading cause of heart failure in patients with chronic diabetes, with unclear mechanisms and limited treatments. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system. Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown. In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.

Key Points: 
  • Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown.
  • In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.
  • Their findings, available online on 17 August 2023, were published in Volume 13, Issue 12 of the journal in December 2023.
  • Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®

Retrieved on: 
Monday, November 27, 2023
Economics, Pressure, Microbiology, Clinical trial, Sepsis, FDA, Laboratory, BRKR, MALDI, Blood culture, Acceleration, Sirius (instrumental), Legislation, Fine chemical, Medical device, Bruker

TUCSON, Ariz., Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification. This agreement enables both companies to validate the use of Accelerate Diagnostics' Arc™ system, an innovative, automated positive blood culture sample preparation platform, with Bruker's MALDI Biotyper® sirius instruments and Sepsityper® software for subsequent registration in both the US and EMEA markets.

Key Points: 
  • Designed for clinical laboratories, the Arc™ system has a simple load-and-go workflow that automates direct from positive blood culture sample preparation for downstream microbial identification using Bruker's MALDI Biotyper system.
  • The Arc™ system enables on-demand processing of samples without the need for an overnight culture incubation, reducing the wait time for identification results.
  • "The combination of Bruker's MALDI Biotyper with Accelerate Diagnostics' Arc™ system to automate positive blood culture sample preparation and rapid microbial identification will be a valuable addition to many laboratories.
  • Bruker welcomes this collaboration with Accelerate Diagnostics as both companies are committed to help laboratories in the important fight against sepsis with their leading products" said Wolfgang Pusch, President, Bruker Microbiology & Infection Diagnostics.

BioFlyte Successfully Validates Aerosolized Fentanyl Detection Capabilities

Retrieved on: 
Thursday, September 28, 2023
Research, Software, Other Defense, Medical Devices, Contracts, Infectious Diseases, Hardware, Health Technology, Science, Government Technology, Security, Technology, Biotechnology, Nanotechnology, Health, Public Safety, Defense, White House, Federal Government, State, Local, Homeland Security, Other Health, General Health, Public Policy, Government, Air, Transport, Pharmaceutical, Other Science, Other Technology, Xylazine, MALDI, Face, Classification, History, Ricin, Collection, Small nucleolar RNA R64/Z200 family, V, Paracetamol, Homeland security, Anthrax, Fentanyl, Pittsburgh International Airport, Risk management

“BioFlyte’s mission is to protect people and critical infrastructure, while also ensuring the continuity of operations in the face of evolving biological and chemical threats,” said Todd Sickles, CEO of BioFlyte.

Key Points: 
  • “BioFlyte’s mission is to protect people and critical infrastructure, while also ensuring the continuity of operations in the face of evolving biological and chemical threats,” said Todd Sickles, CEO of BioFlyte.
  • “Key decision makers in government and public safety are struggling to control the flow of fentanyl into the country.
  • Our ability to quickly and accurately detect life-threatening chemical threats like fentanyl, in addition to serious biological agents sets us apart from every other solution on the market.
  • In testing with Avarint, the BioTOF was exposed to both pure fentanyl and fentanyl mixed with common cutting agents such as xylazine and acetaminophen.

Bruker Introduces Novel 4D-Proteomics™ timsTOF® Capabilities

Retrieved on: 
Monday, September 18, 2023
Research, Technology, Medical Supplies, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, Science, Informatics, LC, BRKR, MALDI, Urine, Serum, TIMS, SP3, Pathology, University of Mainz, Proteomics, Demichev, Multimedia, PG, Biomarker, DDA, Assistant, Associate, Harvard Medical School, Plasma, De novo peptide sequencing, Protein, Acquisition, Kyoto University, Saliva, LC-MS, Ultra, CCS, CSF, MS/MS, Hospital, Fluid mechanics, LC/MS, Boston Children's Hospital, Peptide, Fine chemical, Bruker

View the full release here: https://www.businesswire.com/news/home/20230918138030/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230918138030/en/
    Bruker introduces TIMSquant a scalable, CCS-enabled AI-powered label-free quantification algorithm integrated into Bruker ProteoScape™.
  • We leverage the robustness of our timsTOF instruments and real-time Bruker ProteoScape to build large spectral libraries and analyze 1000s of clinical research samples.
  • Bruker is initiating a limited early-access program for midia-PASEF for immunopeptidomics and post-translational modifications (PTMs) on the ultra-sensitive timsTOF Ultra.
  • To all colleagues in search of top-tier high-throughput data, I endorse the PepSep MAX HT.”
    To ensure optimal run conditions for every sample, Bruker introduces TwinScape™, a digital twin for the timsTOF platform, using Bruker ProteoScape software and the Biognosys iRT kit.

BioFlyte Launches First-of-Its-Kind Biothreat Surveillance Pilot Program at Pittsburgh International Airport

Retrieved on: 
Tuesday, August 22, 2023
Hardware, Other Defense, Contracts, Security, Technology, Nanotechnology, Transportation, General Health, Travel, Defense, Air, Transport, Biotechnology, Science, Other Science, Health, PIT, Partnership, Pittsburgh International Airport, Atmosphere, Aviation, Matrix-assisted laser desorption/ionization, Multimedia, HVAC, Collection, Algorithm, Bacteria, Robotics, Virus, Safety, MALDI, Risk management

BioFlyte , a bioaerosol surveillance firm with a disruptive new class of fieldable biological threat collection, detection and identification solutions, today announced a comprehensive pilot program with Pittsburgh International Airport (PIT) to utilize its fieldable mass spectrometer to add a new layer of safety for the airport.

Key Points: 
  • BioFlyte , a bioaerosol surveillance firm with a disruptive new class of fieldable biological threat collection, detection and identification solutions, today announced a comprehensive pilot program with Pittsburgh International Airport (PIT) to utilize its fieldable mass spectrometer to add a new layer of safety for the airport.
  • As a part of this pilot program, one of BioFlyte’s modules is stationed within the airport’s HVAC system to provide continuous, autonomous surveillance of the air moving through the terminals.
  • “This is the first time a biothreat surveillance technology of this caliber has been operationally introduced into this type of complex critical infrastructure,” said Todd Sickles, CEO, BioFlyte.
  • We are a safer, better airport with them onboard.”
    To learn more about this pilot program and to watch the BioFlyte team demo the technology, see the feature and video on PIT’s Blue Sky News .

BioFlyte Raises $5.4M in Series B Financing to Protect Critical Infrastructure from Airborne Biothreats

Retrieved on: 
Thursday, August 10, 2023
Science, Other Science, Biotechnology, Defense, Other Defense, Health, Technology, Other Technology, Airport, Government, Ricin, Collection, Small nucleolar RNA R64/Z200 family, Cottonwood Technology Fund, Bacteria, Anthrax, Safety, Library, Virus, Fentanyl, Pittsburgh International Airport, MALDI, Risk management

BioFlyte will use this new funding to continue scaling its manufacturing and sales operations to meet customer demand and to develop new product configurations that will serve new markets.

Key Points: 
  • BioFlyte will use this new funding to continue scaling its manufacturing and sales operations to meet customer demand and to develop new product configurations that will serve new markets.
  • “This round of funding will allow us to scale our manufacturing operations and create a sales organization to drive market penetration and support our growing customer base,” said Todd Sickles, CEO, BioFlyte.
  • The z200 provides test results in less than five minutes and operates continuously and autonomously in critical infrastructure environments such as airports, arenas, entertainment venues, and commercial and government buildings.
  • The system consists of a wall mount sensor capable of autonomous detection and identification of airborne toxins in real-time.